Corvus Pharma Gets FDA's Fast-Track for Lymphoma Treatment
By Dean Seal
Corvus Pharmaceuticals said federal regulators have granted fast-track designation to its treatment for relapsed or refractory peripheral T cell lymphoma.
The clinical-stage biopharmaceutical company said Thursday that the Food and Drug Administration granted the special status to soquelitinib for the treatment of T cell lymphoma patients who have already had at least two lines of systemic therapy.
The FDA's fast-track designation facilitates development and expedites the review of drugs that treat serious or life-threatening conditions and have the potential to fill unmet medical needs.
The regulator previously granted soquelitinib orphan-drug designation, which is given to drugs that show promise for potentially treating rare, or orphan, diseases that have fewer than 200,000 cases a year in the U.S.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
August 01, 2024 09:07 ET (13:07 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
3 Dividend Stocks for October 2024
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued